Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial
Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.
Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.
Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder.
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
Eli Lilly and Company will build a $4.5 billion center for advanced manufacturing and drug development in Indiana to innovate new production methods.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com